Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Johns Hopkins Genomics, |
RCV001200880 | SCV001371784 | uncertain significance | Polycystic liver disease 4 with or without kidney cysts | 2020-01-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001313129 | SCV001503608 | uncertain significance | not provided | 2020-07-01 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with LRP5-related conditions. This variant is present in population databases (rs751720886, ExAC 0.002%). This sequence change replaces valine with leucine at codon 713 of the LRP5 protein (p.Val713Leu). The valine residue is weakly conserved and there is a small physicochemical difference between valine and leucine. |
Fulgent Genetics, |
RCV002484073 | SCV002789311 | uncertain significance | Bone mineral density quantitative trait locus 1; Exudative vitreoretinopathy 4; Exudative vitreoretinopathy 1; Worth disease; Autosomal dominant osteopetrosis 1; Osteoporosis with pseudoglioma; Osteoporosis; Polycystic liver disease 4 with or without kidney cysts | 2021-12-09 | criteria provided, single submitter | clinical testing |